Supernus Pharmaceuticals
SUPN
334 hedge funds and large institutions have $2.8B invested in Supernus Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 119 increasing their positions, 114 reducing their positions, and 35 closing their positions.
34% more capital inflows, than outflows
Capital inflows: $362M | Capital outflows: $270M
31% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 35
2.68% more ownership
Funds ownership: 101.13% → 103.81% (+2.7%)
2% more funds holding
Funds holding: 328 → 334 (+6)
4% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 114
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
85% less call options, than puts
Call options by funds: $980K | Put options by funds: $6.64M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$43.9M |
| 2 |
Armistice Capital
New York
|
+$36.1M |
| 3 |
BlackRock
New York
|
+$26.5M |
| 4 |
Millennium Management
New York
|
+$25.8M |
| 5 |
Soleus Capital Management
Greenwich,
Connecticut
|
+$25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$68.2M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$22M |
| 3 |
SG Americas Securities
New York
|
-$16.9M |
| 4 |
Freestone Grove Partners
San Francisco,
California
|
-$15.6M |
| 5 |
MetLife Investment Management
Whippany,
New Jersey
|
-$13M |
SUPN Hedge Fund Activity: Q2 2026 in Review
334 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2026, worth a combined $2.8B — down 6.9% from $3.01B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new SUPN positions and 35 closed out — a net gain of 11 holders — while 119 added to existing stakes and 114 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $43.9M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $68.2M sold.
- 334 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2026, up from 328 in Q1 2026.
- Funds reported $2.8B of Supernus Pharmaceuticals stock for Q2 2026, down 6.9% quarter-over-quarter.
- 46 funds opened new Supernus Pharmaceuticals positions in Q2 2026 and 35 closed out, a net change of +11 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2026 was Two Sigma Investments, an estimated $43.9M added.
- The largest Supernus Pharmaceuticals seller in Q2 2026 was Point72 Asset Management, an estimated $68.2M sold.
Based on aggregated 13F filings for Q2 2026.